Pharmacologically Augmented S-Nitrosylated Hemoglobin Improves Recovery From Murine Subarachnoid Hemorrhage

Huaxin Sheng, MD; James D. Reynolds, PhD; Richard L. Auten, MD; Ivan T. Demchenko, PhD; Claude A. Piantadosi, MD; Jonathan S. Stamler, MD; David S. Warner, MD

Background and Purpose—S-nitrosylated hemoglobin (S-nitrosohemoglobin) has been implicated in the delivery of O₂ to tissues through the regulation of microvascular blood flow. This study tested the hypothesis that enhancement of S-nitrosylated hemoglobin by ethyl nitrite inhalation improves outcome after experimental subarachnoid hemorrhage (SAH).

Methods—A preliminary dosing study identified 20 ppm ethyl nitrite as a concentration that produced a 4-fold increase in S-nitrosylated hemoglobin concentration with no increase in methemoglobin. Mice were subjected to endovascular perforation of the right anterior cerebral artery and were treated with 20 ppm ethyl nitrite in air, or air alone for 72 hours, after which neurologic function, cerebral vessel diameter, brain water content, cortical tissue PO₂, and parenchymal red blood cell flow velocity were measured.

Results—At 72 hours after hemorrhage, air- and ethyl nitrite–exposed mice had similarly sized blood clots. Ethyl nitrite improved neurologic score and rotarod performance; abated SAH-induced constrictions in the ipsilateral anterior, middle cerebral, and internal carotid arteries; and prevented an increase in ipsilateral brain water content. Ethyl nitrite inhalation increased red blood cell flow velocity and cortical tissue PO₂ in the ipsilateral cortex with no effect on systemic blood pressure.

Conclusions—Targeted S-nitrosylation of hemoglobin improved outcome parameters, including vessel diameter, tissue blood flow, cortical tissue PO₂, and neurologic function in a murine SAH model. Augmenting endogenous PO₂-dependent delivery of NO bioactivity to selectively dilate the compromised cerebral vasculature has significant clinical potential in the treatment of SAH. (Stroke. 2011;42:471-476.)

Key Words: brain ■ mouse ■ subarachnoid hemorrhage ■ S-nitrosylated hemoglobin ■ ethyl nitrite

Red blood cells (RBCs) regulate tissue O₂ delivery by using hemoglobin (Hb) as both an O₂ sensor and a transducer of NO vasodilator activity to match local tissue blood flow to that region’s O₂ requirements.¹ Impairment of this microcirculatory interrelationship may occur in pathophysiologic conditions, including subarachnoid hemorrhage (SAH).

After SAH, delayed narrowing of vessels impairs delivery of O₂ and nutrients to brain tissue. This delayed arteriopathy is due, at least in part, to local disruption of NO bioactivity.² Addressing this disruption is problematic. Systemic administration of nonspecific vasoactive agents has shown limited efficacy due to dose-limiting arterial hypotension.³,⁴ Central (directed) administration of NO donors has been reported to be beneficial in some,⁵,⁶ but not other,⁷ applications and is complicated by the need for invasive access. Nonetheless, affected cerebral vessels appear to maintain vasoreactivity,⁸ so a different course of action may be augmentation of the body’s innate ability to selectively increase blood flow to areas of low O₂ tension.

Increasing the circulating pool of physiologic NO bioactivity (that is, S-nitrosothiols, including S-nitrosylated hemoglobin, SNO-Hb) could selectively improve flow to focal ischemic brain tissue without altering flow to other tissue beds. This does not involve the generation of free NO, which is rapidly metabolized by Hb. Instead, hypoxic vasodilation results from a series of transnitrosylation reactions when NO bioactivity is released by the RBC. Accumulating evidence suggests that a small S-nitrosothiol,⁴ S-nitrosogluthatione, which is derived from RBC SNO-Hb, subserves hypoxic regulation of O₂ delivery.⁹–¹¹

The goal of the present study was to test the hypothesis that augmentation of SNO-Hb improves outcome after experi-
mental SAH. We reasoned that increased vessel diameter and enhancement of cortical tissue PO₂ (tPO₂) in the affected cortex would be reflected in improved neurologic outcome. The experiments were conducted in mice and utilized ethyl nitrite (ENO), a selective nitrosylating agent that preferentially forms SNO-Hb12,13 and other nitrosylated thiols on exposure to blood (the other reaction product is ethanol). ENO has not previously been tested as a therapy for a focal pathologic condition such as SAH, but it has shown benefit in a disparate collection of disorders characterized by disruptions in O₂ delivery, including pulmonary hypertension13 and laparoscopic surgery.14

Materials and Methods
The Duke University institutional animal care and use committee approved all aspects of the study design. Experiments were conducted on male C57Bl/6J mice (20 to 25 g; The Jackson Laboratory, Bar Harbor, ME). Gas exposures occurred within a 5.5-L, acryl box kept at room temperature and normal atmospheric pressure. ENO (Custom Gas Solutions, Durham, NC) was blended with N₂ to the desired concentration at the time of delivery. In this SAH model, cerebral vasospasm has been reported to peak 72 hours after SAH.13 We therefore examined mice at this recovery interval in the following studies.

Dose Finding and NO Measurements
Mice (n = 5 per group) were exposed to ENO (0, 20, 40, or 80 ppm) in air for 72 hours. Mice were then anesthetized, and arterial blood (0.5 mL) was sampled via cardiac puncture for determination of total Hb and methemoglobin with a Gem Premier 3000 co-oximeter (Instrumentation Laboratory, Lexington, MA). In a separate set of mice, the 72-hour 20-ppm ENO exposure was repeated to measure final blood SNO-Hb and RBC NO concentrations (that is, FeNO and SNO) by Hg-coupled photolysis/chemiluminescence.16,17 On the basis of the methemoglobin and SNO-Hb values obtained from these experiments and evidence that 10 ppm ENO attenuates lipopolysaccharide-induced lung inflammation,19 we elected to further study 20 ppm (0.002% atm) ENO.

Post-SAH Neurologic Function, Vessel Diameter, and Brain Edema
The following experiments were conducted with animals randomly assigned to experimental groups. SAH was induced in isoflurane-anesthetized, mechanically ventilated mice by endovascular perforation of the anterior cerebral artery (ACA) with a 5-0 nylon monofilament suture, according to previously reported procedures.19,20 Pericranial temperature was maintained at 37.0±0.2°C. After ACA perforation, the mice were awakened. At 60 minutes after SAH, mice were moved to the exposure chamber for 72 hours. Fresh gas inflow was 21% O₂ with (n = 20) or without (n = 23) 20 ppm ENO, balanced with N₂. In a separate experiment, sham mice were subjected to all procedures except ACA perforation. Mice were then anesthetized with orotracheal isoflurane and mechanically ventilated with 30% O₂, balance N₂. A femoral artery was cannulated. A transcranial laser Doppler flow (LDF) probe was positioned over the ventral cerebral cortex. Mean arterial pressure (MAP) and LDF were continuously measured for a 30-minute baseline interval and for 60 minutes after onset of ENO (20 ppm) treatment.

Time-Dependent ENO Effects on Cortical Blood Flow Velocity and Systemic Blood Pressure
Mice were subjected to SAH and exposed to air for 24 or 72 hours or to sham surgery (all procedures except ACA perforation). Mice (n = 3 per group) were then anesthetized with orotracheal isoflurane and mechanically ventilated with 30% O₂, balance N₂. A femoral artery was cannulated. A transcranial laser Doppler flow (LDF) probe was positioned over the ventral cerebral cortex. Mean arterial pressure (MAP) and LDF were continuously measured for a 30-minute baseline interval and for 60 minutes after onset of ENO (20 ppm) treatment.

Acute Effects of ENO on Brain tPO₂ 72 Hours After SAH
Brain tPO₂ was measured according to a previously described polarographic method.24 Mice were exposed to SAH or sham surgery (n = 6 per group) and treated with air during 72 hours of recovery. Mice were then anesthetized with 10% isoflurane in 30% O₂, balance N₂. A femoral artery was cannulated. A 10-μm-diameter Pt microelectrode was inserted 1 mm into the cortex. LDF and tPO₂ were recorded every 5 minutes. After 30 minutes of stabilization, 20 ppm ENO was added to the inspired gas mixture. Measurements continued for 60 minutes. Arterial blood gas/glucose values were then measured.

Statistical Analysis
Power calculations with this model indicated that 20 mice per experimental group would have an 80% power to detect a 30% difference in MCA diameter.20 Nonparametric values (neurologic score, hemorrhage size, and tissue optical density) were compared by the Mann–Whitney U statistic and are reported as median±interquartile range. Physiologic values, rotorad latency, vessel diameter, and brain water content were compared with the unpaired Student’s t test. The paired Student’s t test was used to compare baseline values of MAP, LDF, and tPO₂ versus those at 60 minutes after ENO exposure onset. Methemoglobin and Hb concentrations were compared by 1-way ANOVA. Parametric values are reported as mean±SD.

Results
Blood Parameters
There were no differences among groups for total Hb (0 ppm=14±1, 20 ppm=15±1, 40 ppm=14±1, 80 ppm=14±1

---

Downloaded from http://stroke.ahajournals.org/ by guest on April 20, 2017
Methemoglobin was increased by 40 and 80 ppm ENO (0 ppm ENO 0.08). ENO (20 ppm) increased SNO-Hb and total RBC NO (Figure 1). Post-SAH Neurologic Function and Vessel Diameter

Three SAH mice died during the 72-hour recovery interval (1 from the ENO group and 2 from the air-only group). This was likely due to intracranial hypertension.25 There was no intergroup difference in body weight change from baseline (SAH-air 3.2g, SAH-ENO 2.2g; P 0.25). SAH grades were similar (air=4±0.25, ENO=4±0; P=0.27). ENO improved 72-hour post-SAH neurologic scores (P=0.009, Figure 2A) and rotarod performance (P=0.003, Figure 2B). Right ACA, MCA, and ICA diameters were greater in the ENO group (Figure 3). There was no effect of ENO on vessel diameters in shams. Basilar artery diameters were similar among groups (sham-air=179±12 µm, sham-ENO=172±12 µm, SAH-air=183±2 µm, SAH-ENO=187±11 µm; P=0.61). This indicates that the effects of ENO were injury-specific, because there was no clot in this location. Relative tissue optical density was greater with ENO (SAH-air=1.17±0.04 vs SAH-ENO=1.23±0.02, P<0.0001), with values similar to shams (sham-air=1.23±0.01, sham-ENO=1.23±0.02).

Edema, LDF, MAP, and Cortical tPo2

ENO decreased cerebral edema in the hemisphere ipsilateral to the hemorrhage (Figure 4). In anesthetized shams, 20 ppm ENO inhalation did not alter MAP or LDF (Figure 5A). Mice were allowed to survive 24 or 72 hours after SAH in air. At 24 hours, the ENO LDF response was episodic, indicating an unstable effect of ENO at this stage of disease progression (Figure 5B). Although MAP remained constant, acute ENO administration

Figure 1. Preferential S-nitrosylation of Hb. RBC NO bioactivity after 72 hours of air or 20 ppm ENO inhalation. A, SNO-Hb, and B, total Hb NO. Values are mean±SD (n=5 per group).

Figure 2. Post-SAH neurologic function. Mice were treated with either air (n=21) or 20 ppm ENO (n=19) for 72 hours after SAH. ENO improved neurologic score (A) (0=no deficit, P=0.009) and rotarod latency to fall (B) (P=0.003). Open circles indicate individual mouse values. Horizontal bars indicate median values for neurologic score and mean values for rotarod. There was no effect of ENO on sham (n=5) performance (P>0.99, P=0.25, respectively).

Figure 3. Cerebral vessel diameters. Diameters of the ACA (A), MCA (B), and ICA (C) ipsilateral to the right ACA perforation were measured after 72 hours of treatment with air (n=21) or 20 ppm ENO (n=19). ENO increased post-SAH diameter in the ACA (P=0.003), MCA (P=0.04), and ICA (P<0.0001). Open circles indicate individual mouse values. Horizontal bars indicate mean values. There was no effect of ENO on sham (n=5) vessel diameters (P=0.85).
rapidly and consistently improved LDF at 72 hours (Figure 5C), indicating that the postinjury vasculature can still respond to an increase in SNO-Hb. Another set of SAH and sham mice recovered for 72 hours in air. Acute ENO inhalation increased both LDF and cortical tPO2 (Figure 6), with no effect on MAP. At completion of the experiment, pH=7.36±0.07, Paco2=35±7 mm Hg, Pao2=163±34 mm Hg, and glucose=169±49 mg/dL.

Discussion

Inhaled ENO improved neurologic deficits attributable to experimental SAH. This was associated with greater vessel diameter, decreased brain edema, and improved LDF and tPO2, but ENO had no effect on MAP. ENO increases tissue oxygenation selectively in the ischemic brain and suggests that SNO-Hb provides a route to regulate microvascular blood flow.

The release of NO bioactivity from SNO-Hb is regulated allosterically by O2 saturation: NO bioactivity is liberated preferentially in environments that favor O2 offloading. Decreased tPO2 occurs in clinical SAH. After SAH, tPO2 values observed in this experiment were increased to a viable range by ENO (for example, 32±10 mm Hg). A likely
basis for this response was an ENO-induced increase in circulating SNO-Hb concentration. MAP remained unaffected by ENO, as did LDF in the unaffected cortex, consistent with the normal tPO2 values in sham-operated animals. This hypoxic selectivity provides perhaps the most clinically relevant attribute of pharmacologically increased SNO-Hb.

A target for S-nitrosylation is the β93 cysteine thiol in Hb. The extent to which Hb is S-nitrosylated is dependent on the Hb oxygenation state. Oxymyoglobin is readily nitrosylated and causes the S-nitrosothiol to face inward, protecting the NO moiety from solvent. In the deoxy state, the cysteine residue is allosterically rotated outward into the blood phase, thereby enabling SNO-Hb to transnitrosylate other moieties. Thus, SNO-Hb provides a hypoxia-activated source of NO bioactivity that constitutes a basis for increased delivery of O2 to a hypoxic region.

There have been brief human exposures to ENO. Treatment of chronic pulmonary hypertension with ENO (0 to 70 ppm) by facemask increased SNO-Hb, decreased pulmonary artery pressure and resistance, and increased arterial PO2 without affecting systemic vascular resistance or MAP. Critically ill newborns with persistent pulmonary hypertension were exposed to ENO concentrations of up to 80 ppm, which dose-dependently increased arterial O2 saturation. Methemoglobin levels remained in a clinically acceptable range. Humans have not undergone sustained ENO exposure. Although we saw no adverse effects in mice exposed to ENO for 72 hours, the clinical course of delayed arteriopathy after SAH is many days. It remains to be determined whether sustained ENO exposure is required to provide benefit. It is noteworthy that prolonged ENO exposure served to abate vasospasm onset and that acute ENO exposure 72 hours after SAH provided beneficial effects on tPO2 and LDF once vasospasm had become established.

S-nitrosylation of proteins may play other roles in SAH. S-nitrosylation inhibits both caspase-3 and nuclear factor-κB activation, thereby attenuating inflammation and cell death. Treatment with ENO blocks nuclear factor-κB activation in acute lung injury. The N-methyl-D-aspartate receptor undergoes S-nitrosylation during hyperexcitation associated with hypoxia, with S-nitrosylation inhibiting N-methyl-D-aspartate–evoked currents. Apoptosis, nuclear factor-κB activation, and elevated glutamate are known SAH consequences. Although we have provided direct evidence of improved tissue perfusion and tPO2 from ENO, favorable effects on cellular events may have also contributed to improved neurologic function.

ENO improved acute recovery from murine SAH. Adverse effects were not observed. Pharmacologic enhancement of SNO-Hb provides a novel strategy for SAH therapeutic intervention. Optimal ENO dosing strategies, the presence of sustained efficacy in long-term outcome analyses, direct comparison with established treatments, and confirmation of purported molecular mechanisms of action require continued investigation.

Sources of Funding
This study was supported by US Public Health Service grants 5R21NS063108, 5R21NS0858321, RO1HL091876, and RO1HL095463.

Disclosures
Duke University has filed a use patent application for ENO in SAH. Individual authors have no conflicts of interest to disclose.

References


Pharmacologically Augmented S-Nitrosylated Hemoglobin Improves Recovery From Murine Subarachnoid Hemorrhage


Stroke. 2011;42:471-476; originally published online December 30, 2010;
doi: 10.1161/STROKEAHA.110.600569

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/42/2/471